Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $17.93.

Several research firms recently weighed in on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America increased their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $12.36 on Monday. The company has a market cap of $9.00 billion, a price-to-earnings ratio of 2.19 and a beta of 1.25. Roivant Sciences has a 1 year low of $9.48 and a 1 year high of $13.06. The firm has a fifty day moving average price of $11.82 and a 200-day moving average price of $11.41.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at approximately $7,193,525.50. This represents a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the transaction, the director now owns 22,179,358 shares of the company’s stock, valued at $262,160,011.56. This represents a 3.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,677,309 shares of company stock valued at $43,283,184 in the last three months. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds have recently bought and sold shares of the business. Gladius Capital Management LP bought a new stake in shares of Roivant Sciences in the 3rd quarter worth about $35,000. nVerses Capital LLC bought a new stake in Roivant Sciences during the second quarter worth approximately $34,000. US Bancorp DE increased its stake in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after acquiring an additional 1,948 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences during the second quarter valued at approximately $36,000. Finally, Quarry LP bought a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $53,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.